Tags: Novo Nordisk
Novo Nordisk Now The 12th Most Valuable Company After Positive Weight Loss Pill Trial, Surpassing Tesla
The successful weight loss trial of the amycretin pill pushed Novo Nordisk past Tesla in market value to $604 billion, increasing investor interest in innovative solutions for major health issues like obesity.
Novo Nordisk to promote drug to treat obesity in United States
Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday.
Novo AS Invests in Ophthotech Corporation
Novo AS invests in Ophhtotech Corporation for the further development of drug Fovista. In an announcement made today, Ophthotech Corporation said it was able to raise US$175 million in funding to finance the global Phase 3 clinical program of its lead medication Fovista.
